You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The companies will work together to create an end-to-end workflow for biomarker and drug target validation, and assay development.
The company will provide oncology specimens and associated clinical data to the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium.
5AM Solutions will develop software that will allow Asterand to electronically link multiple biorepositories and identify, annotate, and distribute biospecimen data internally and with collaborators.
The contract to supply biospecimens for the Cancer Genome Atlas project could reach a total value of $24 million.
BioSeek will apply its BioMap predictive human disease models to screen Amylin's library.
The Japanese pharmaceutical developer has licensed the BioMap platform for drug toxicology research projects.
BioSeek will use its BioMap system to conduct screening for Ono Pharmaceuticals in its compound studies.
Affymetrix, Febit, Asterand, ImaGenes
BMS will continue to use Asterand's tissue-based drug-discovery products and services for up to three years.
The acquisition will combine Asterand's tissue-based services for drug discovery with BioSeek's BioMap platform and human cell-based assays.
Nature News reports on the US National Science Foundation's investigations of undisclosed foreign ties among researchers it funds.
Researchers have developed a set of 10 principles to guide how a list of all species on earth should be put together, the Guardian reports.
Wired reports on a new firm developing a gene writing approach for therapeutic genome changes.
In Nature this week: a method called cis-X combines whole-genome and transcriptome sequencing data to identify regulatory noncoding variants, and more.